Company profile: Array BioPharma
1.1 - Company Overview
Company description
- Provider of targeted small molecule drugs, focused on the development and commercialization of treatments for cancer and other high-burden diseases. Partnered drugs include binimetinib (MEK162), encorafenib (LGX818), selumetinib (with AstraZeneca), and danoprevir (with Roche).
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Array BioPharma
Sesen Bio
HQ: United States
Website
- Description: Provider of protein-based therapeutics focused on improving human health, including Vicineum, a locally administered targeted fusion protein for BCG-unresponsive non-muscle invasive bladder cancer, and VB6-845d, an anti-PSMA humabody-deBouganin fusion protein designed for tumor cell killing and overcoming drug resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sesen Bio company profile →
Juno Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapies for the treatment of cancer, formed through a unique partnership with Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute to advance a broad pipeline of breakthrough immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Juno Therapeutics company profile →
Relay Therapeutics
HQ: United States
Website
- Description: Provider of an allosteric drug-discovery platform applying computational techniques to protein motion. Offers the Dynamo Platform integrating experimental and computational methods on protein dynamics and a pipeline in precision oncology and genetic diseases, including RLY-4008 (FGFR2), RLY-2608 (pan mutant-selective PI3Kα), and RLY-1971 (SHP2), all in early clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Relay Therapeutics company profile →
MolecularMD
HQ: United States
Website
- Description: Provider of specialty molecular diagnostics products and services for oncology, supporting clinical development and commercialization of cancer therapies. Offers tests to enable appropriate selection, monitoring, and management of patients treated with molecularly targeted cancer therapies, incorporating both gold-standard and innovative assay technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MolecularMD company profile →
IntraOp
HQ: United States
Website
- Description: Provider of compact, mobile electron therapy devices and platforms for cancer treatment, including Mobetron, a self-shielded electron-beam linear accelerator for intraoperative radiation therapy; FLASH-IQ, delivering UHDR electron beams for preclinical and investigational FLASH radiotherapy; and non-invasive electron therapy for non-melanoma skin cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IntraOp company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Array BioPharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Array BioPharma
2.2 - Growth funds investing in similar companies to Array BioPharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Array BioPharma
4.2 - Public trading comparable groups for Array BioPharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →